GILD Gilead Sciences Inc.

65.93
-0.82  -1%
Previous Close 66.75
Open 66.9
Price To Book 4.05
Market Cap 83,411,050,199
Shares 1,265,145,612
Volume 5,847,759
Short Ratio
Av. Daily Volume 6,051,684
Stock charts supplied by TradingView

NewsSee all news

  1. National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco

    Grant Will Support the Transfer of The Quilt, its Programs and a New Public Education Initiative to Reach Communities Adversely Impacted by HIV Today, the National AIDS Memorial and Gilead Sciences, Inc. (NASDAQ:GILD)

  2. Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite

    -- Charles Calderaro and Ken Takeshita, MD to Join Kite's Leadership Team -- Kite, a Gilead Company (NASDAQ:GILD), today announced two new additions to the company's leadership team. Charles Calderaro will join Kite as

  3. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  4. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  5. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 trial did not meet primary endpoint - February 11, 2019.
Selonsertib (GS-4997) - STELLAR 4
Nonalcoholic steatohepatitis (NASH)
Phase 2 enrollment completed 1Q 2018.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Sjogren’s syndrome
Phase 3 enrolment to be completed 2H 2020.
Cilofexor (GS-9674)
Primary sclerosing cholangitis
Phase 2 data released November 9, 2018.
GS-9674
Primary biliary cholangitis
Phase 2 trial to complete enrolment 3Q 2019.
GS-5734
Ebola
FDA Approval announced October 3, 2019.
F/TAF (Descovy)
Pre-exposure prophylaxis
Phase 2 data due 1H 2020.
Axicabtagene ciloleucel - (ZUMA-5)
Indolent B-Cell Non-Hodgkin Lymphoma
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib
Psoriatic arthritis
Phase 3 futility analysis 3Q 2017. Trial to continue.
Andecaliximab GS-5745
Gastric Cancer
Approved February 7, 2018.
Bictegravir/F/TAF
HIV
Phase 2 data 4Q 2018.
GS-9674
Nonalcoholic steatohepatitis (NASH)
Phase 3 data April 25, 2019 did not meet primary endpoint.
Selonsertib (GS-4997) - STELLAR 3
Nonalcoholic steatohepatitis (NASH)
Phase 2 data released October 24, 2017. Positive high dose data, low dose negative.
GS-0976
Nonalcoholic steatohepatitis (NASH)
Approval announced July 18, 2017.
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
Hepatitis C virus (HCV)
Phase 2 ongoing.
Entospletinib
Chronic Graft Versus Host Disease (cGVHD)
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 4Q 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 data due 4Q 2019.
Axicabtagene ciloleucel - (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 pivotal trial enrolment completed 3Q 2019.
Axicabtagene ciloleucel - (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 1/2 data released 2Q 2019.
Axicabtagene ciloleucel - (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
2-year data at ASH 2018 noted 39% of patients were in an ongoing response. OS not yet reached.
Yescarta (axicabtagene ciloleucel)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer
Phase 1/2 data due 1H 2020.
Axicabtagene ciloleucel (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 data due 1H 2020.
Axicabtagene ciloleucel (ZUMA-8)
Chronic lymphocytic leukemia (CLL)
Phase 2 data due 4Q 2019.
GS-9131
HIV
Phase 3 enrollment to be completed 4Q 2019.
Axicabtagene ciloleucel (ZUMA-7)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2b 48-week data due 4Q 2019.
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial initiated 3Q 2019.
Selonsertib (GS-4997)
Diabetic kidney disease
Phase 1 initial data due 1H 2020.
Axicabtagene ciloleucel - KTE-C19 (ZUMA-11)
Phase 2 data due 4Q 2019.
GS-9688
HBV
Phase 2 trial initiated 4Q 2019.
Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)
Phase 2 enrolment to be completed 1H 2020.
Axicabtagene ciloleucel - (ZUMA-12)
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 trial to be initiated 4Q 2019.
GS-4875
Ulcerative Colitis

Latest News

  1. National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco

    Grant Will Support the Transfer of The Quilt, its Programs and a New Public Education Initiative to Reach Communities Adversely Impacted by HIV Today, the National AIDS Memorial and Gilead Sciences, Inc. (NASDAQ:GILD)

  2. Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite

    -- Charles Calderaro and Ken Takeshita, MD to Join Kite's Leadership Team -- Kite, a Gilead Company (NASDAQ:GILD), today announced two new additions to the company's leadership team. Charles Calderaro will join Kite as

  3. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  4. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  5. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

  6. Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

    ─ Phase 1 Results Support Up to Six-month Dosing Interval and Advancement Into Later-Stage Clinical Trials ─ Gilead Sciences, Inc. (NASDAQ:GILD) today announced data on GS-6207, an investigational, novel, selective,

  7. Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

    -- AI-Based Tools for Liver Histology Assessment Contribute to Gilead's Broader Efforts to Improve Understanding of NASH -- -- Data Support Utility of Noninvasive Tests (NITs) for Risk Stratification and Monitoring of

  8. Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019

    -- Data Demonstrate Reductions in Hepatocellular Carcinoma in Hepatitis B (HBV) Patients Treated with Vemlidy -- -- Improved Markers of Bone and Renal Safety Also Seen with Vemlidy in Separate Analysis of HBV Patients

  9. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  10. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  11. Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019

    -- Survival Data at Three Years in ZUMA-1 and Results from Study Cohort Evaluating Safety and Efficacy of Earlier Steroid Use with Yescarta® (axicabtagene ciloleucel) in Large B-cell Lymphoma to be Presented -- --

  12. Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®

    – Results Continue to Demonstrate Statistically Significant Advantages of Descovy® Over Truvada® for Study Measurements of Bone and Renal Safety – Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results

  13. Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials

    – Data from the Two 144-week Studies in Treatment-naïve Adults Living with HIV Presented at European AIDS Conference (EACS)– Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from two randomized,

  14. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  15. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  16. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  17. Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases Gilead Sciences, Inc. (NASDAQ:GILD)

  18. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  19. Gilead Sciences Announces Fourth Quarter 2019 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.63 per share of common stock for the fourth quarter of 2019. The dividend is payable on

  20. Gilead Sciences Announces Third Quarter 2019 Financial Results

    - Product Sales of $5.5 billion - - GAAP Loss of $0.92 per share - - Non-GAAP Diluted EPS of $1.75 per share - - Revised Full Year 2019 Guidance - Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results

  21. Gilead Sciences Appoints Andrew Dickinson as Chief Financial Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Andrew Dickinson has been appointed Chief Financial Officer (CFO), effective November 1. Mr. Dickinson currently serves as the company's Executive Vice President,

  22. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  23. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  24. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  25. Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 2019

    -- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30

  26. Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has

  27. Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company's global clinical

  28. Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019

    - Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP™ - - Analysis Illustrates the Significant and Independent Impact of

  29. U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP)

    - Descovy Demonstrated Non-inferior Efficacy and an Improved Bone and Renal Safety Profile Compared with Truvada® in People at Risk for Sexually Acquired HIV Infection in a Global Phase 3 Trial - Gilead Sciences, Inc.

  30. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  31. Gene Therapy Treatments Offer Hope for Cancer Patients

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ:GNPX) (GNPX Profile) is focused

  32. Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Morgan

  33. Alberta Provides Access to Biktarvy® for the Treatment of HIV

    Gilead Canada recognizes the Government of Alberta for providing access to new treatment for people living with HIV In 2017, Alberta accounted for 11.7 per cent of reported HIV cases in Canada1 In clinical trials,

  34. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information –   Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global

  35. Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release